DDInter425 DDInter119
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Cobimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cobimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminoglutethimide
Cobimetinib {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Cobimetinib {u} may lead to a major life threatening interaction when taken with {v} Imatinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Cobimetinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Cobimetinib may lead to a major life threatening interaction when taken with Imatinib